Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 X Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
crossref(2023)
摘要
Shows Phenotype, Viability, and Cytotoxicity of the Product.
更多查看译文
关键词
Metastatic Prostate Cancer,T Cell Therapy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要